EGFR and non-small cell lung carcinoma: Contrary to ‘disease flare’ that withdrawal of EGFR-TKI from patients with the mutated EGFR-lung cancer progresses the tumours54, the effect of ‘ROS1-TKI addiction’ might regress the tumours in the mutated ROS1 fusion-positive NSCLC when ROS1-TKI is withdrawn from the patients.